Company / Gross Profit per Share
Haemonetics Gross Profit per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit per Share
$14.85
FY2024
5-year range
$9.84 / $14.85
FY2020-FY2024
Trend
+10.3%
vs FY2023
Sector context
#35 of 94
Health Care
What the data says
At $14.85, Haemonetics's gross profit per share ranks #35 of 94 in the Health Care sector. Gross Profit per Share has increased for 4 consecutive years, from $7.76 in FY2020 to $14.85 in FY2024.
Based on SEC 10-K filings.
14.85 in FY2024 with a 5-year CAGR of +9.7%.
Improved from $11.96 to $14.85 over the past 2 years.
Health Care sector context is included.
Gross Profit per Share over time
Growth rates
- 3-Year CAGR
- +14.7%
- 5-Year CAGR
- +9.7%
- 10-Year CAGR
- -
Sector benchmark
#35 of 94 in Health CareTop 37% of 94This company $14.85 Sector average $14.63
▼
+1.5% above sector average
Key checks
Key Insights
- Haemonetics's gross profit per share has grown for 4 consecutive years.
- In FY2024, gross profit per share increased 10.3% year-over-year.
- Ranks #35 out of 94 companies in the Health Care sector.
- Lowest gross profit per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross Profit per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $14.85 | +10.3% |
| FY2023 | $13.46 | +12.5% |
| FY2022 | $11.96 | +21.5% |
| FY2021 | $9.84 | +26.9% |
| FY2020 | $7.76 | -17.1% |
| FY2019 | $9.35 | +17.0% |
| FY2018 | $7.99 | -1.2% |
| FY2017 | $8.09 | +10.4% |
| FY2016 | $7.33 | -6.1% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026